Literature DB >> 20085590

Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression.

Kathryn Effendi1, Taisuke Mori, Mina Komuta, Yohei Masugi, Wenlin Du, Michiie Sakamoto.   

Abstract

Overexpression of "stemness gene"Bmi-1 has been identified in some solid tumors. We investigated Bmi-1 expression in hepatocellular carcinoma (HCC) and ATP-binding cassette transporter B1 (ABCB1) as a new potential target for Bmi-1. Bmi-1 was highly expressed in HCC cell lines and the most well differentiated cell line, KIM-1, showed the highest expression. Immunohistochemical, immunocytochemical, and immunoelectron microscopic analysis showed the Bmi-1 protein as having a high intensity of small dots within the nucleus which reflected concentrated sites of Bmi-1 repressive activity. Clear "dot-pattern" staining was observed in 24 of 37 (65%) well differentiated HCC (including 13 of 21 early nodules [62%]), in 32 of 71 (45%) moderately differentiated HCC, and 7 of 14 (50%) poorly differentiated HCC. A similar expression was not observed in non-cancerous background regions. High Bmi-1 expression was observed in the early and well differentiated HCC. Furthermore, overexpression and suppression of Bmi-1 was followed by a respective increase and decrease in ABCB1 expression. As with Bmi-1, high ABCB1 expression was also observed in the early and well differentiated HCC. A strong correlation between ABCB1 and Bmi-1 mRNA expression was seen in HCC cell lines and clinical samples (Pearson's correlation coefficient 0.95 and 0.90, respectively). The Bmi-1 gene is upregulated in HCC, and in particular is highly expressed in early and well differentiated HCC. The fact that this expression correlated with that of ABCB1 suggests a new regulation target for Bmi-1, and gives new insight into early hepatocarcinogenesis mechanisms and potential targets for future HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20085590     DOI: 10.1111/j.1349-7006.2009.01431.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  17 in total

1.  Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.

Authors:  Monica Bartucci; Mohamed S Hussein; Eric Huselid; Kathleen Flaherty; Michele Patrizii; Saurabh V Laddha; Cindy Kui; Rachel A Bigos; John A Gilleran; Mervat M S El Ansary; Mona A M Awad; S David Kimball; David J Augeri; Hatem E Sabaawy
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

2.  Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.

Authors:  Fang Yang; Li-Zhi Lv; Qiu-Cheng Cai; Yi Jiang
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

3.  p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma.

Authors:  Dragana Kopanja; Shuo Huang; Mohamed Rizwan Haroon Al Raheed; Grace Guzman; Pradip Raychaudhuri
Journal:  Carcinogenesis       Date:  2018-03-08       Impact factor: 4.944

Review 4.  Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins.

Authors:  Sandy Leung-Kuen Au; Irene Oi-Lin Ng; Chun-Ming Wong
Journal:  Front Med       Date:  2013-04-26       Impact factor: 4.592

5.  miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

Authors:  Shujing Liu; Michael T Tetzlaff; Rutao Cui; Xiaowei Xu
Journal:  Am J Pathol       Date:  2012-09-13       Impact factor: 4.307

Review 6.  Epigenetic regulation in hepatocellular carcinoma requires long noncoding RNAs.

Authors:  Laura Amicone; Franca Citarella; Carla Cicchini
Journal:  Biomed Res Int       Date:  2015-03-10       Impact factor: 3.411

7.  Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.

Authors:  Wen-rui Wu; Hong Sun; Rui Zhang; Xian-huan Yu; Xiang-de Shi; Man-sheng Zhu; Hong Zeng; Li-xu Yan; Lei-bo Xu; Chao Liu
Journal:  Oncotarget       Date:  2016-04-05

8.  The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis.

Authors:  Run Zhai; Fang Tang; Jianhua Gong; Jing Zhang; Biao Lei; Bo Li; Yangchao Wei; Xingsi Liang; Bo Tang; Songqing He
Journal:  Onco Targets Ther       Date:  2016-11-24       Impact factor: 4.147

9.  Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.

Authors:  Bo Tang; Zhigao Hu; Yang Li; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Songqing He
Journal:  Mol Med Rep       Date:  2015-11-06       Impact factor: 2.952

10.  Early hepatocellular carcinoma with high-grade atypia in small vaguely nodular lesions.

Authors:  Hidenori Ojima; Yohei Masugi; Hanako Tsujikawa; Katsura Emoto; Yoko Fujii-Nishimura; Mami Hatano; Miho Kawaida; Osamu Itano; Yuko Kitagawa; Michiie Sakamoto
Journal:  Cancer Sci       Date:  2016-03-18       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.